查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495988

腫瘤消融市場：2024-2029 年預測

Tumor Ablation Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年腫瘤消融市值為12.91億美元，預計複合年成長率為12.10%，到2029年市場規模將達到28.72億美元。

通常用於治療肺、腎、肝、骨等腫瘤和癌症的影像導引技術稱為「腫瘤消融」。腫瘤消融技術的高效率和成本效益正在推動全球市場的需求。此技術通常透過冷凍、射頻消融術和微波消融等不同方式進行。

腫瘤消融中採用的影像技術為早期腫瘤診斷和預防提供了有效的結果。癌症和腫瘤病例數的增加正在增加全球市場對腫瘤消融技術的需求。人們對癌症的認知不斷提高，以及早期診斷和治療癌症的需求正在推動這些技術在全球範圍內的市場價值。

隨著醫療機構和腫瘤醫院的增多，腫瘤消融技術正變得越來越多的人能夠接觸到。診斷效率和成本效益正在提高腫瘤消融在全球市場的可接受性和應用。此外，領導企業在腫瘤消融研發領域的加大投入也為全球腫瘤消融市場的成長提供了機會。

政府和機構提供的支持也提高了腫瘤消融技術的可接受性和可用性。老年人口的增加和腫瘤發生率的增加也是推動全球腫瘤消融市場成長的關鍵因素之一。

市場促進因素：

  • 癌症患者數量的增加預計將推動全球腫瘤消融市場的發展。

癌症病例數量的增加和癌症患者數量的增加是推動全球腫瘤消融市場成長的主要因素之一。人們的生活方式和現代飲食正在增加人們腫瘤和癌症的發生率。此外，腫瘤數量的增加也增加了全球市場對腫瘤消融等治療和診斷方法的需求。

根據美國癌症協會的資料，美國每年診斷出約 1,762,450 例癌症和腫瘤新病例。癌症病例和癌症死亡率的上升正在推動美國市場對腫瘤消融的需求。根據美國癌症協會統計，美國有 606,880 人死於癌症。低效率的診斷和治療技術導致全世界癌症和腫瘤死亡。

世界衛生組織（WHO）聲稱，經濟不穩定的國家比經濟穩定的國家有更多的腫瘤和癌症病例。國際癌症控制聯盟 (IUCC) 指出，全世界六分之一的死亡是由於癌症或腫瘤造成的。據報道，在經濟較不穩定和低度開發國家，癌症死亡率約 70%。對更好的診斷技術和治療方法的需求正在推動全球腫瘤消融市場的發展。對腫瘤消融技術不斷成長的需求和需求正在推動全球腫瘤消融市場的需求和市場價值。

  • 消融設備的技術進步將推動市場成長

消融設備研發技術的進步和升級正在刺激全球腫瘤消融市場的成長。多家公司的高額研發投資正在增加全球醫療保健和醫療領域腫瘤消融的全球市場佔有率。此外，全球醫療保健和醫療領域的不斷進步和開拓正在推動腫瘤消融技術市場達到一定水平。

冷凍消融、微波消融和其他技術的引入是推動全球腫瘤消融市場發展的某些發現。現代技術在癌症治療和診斷的應用，將腫瘤消融技術提升到了新的水平。根據IUCC（國際癌症控制聯盟）的報告，約1,670億美元用於癌症治療的研究和開發過程。

預計北美將主導市場。

預計北美地區將在預測年內主導全球腫瘤消融市場。該地區政府機構和多家公司增加對癌症治療和診斷技術的投資是推動腫瘤消融市場成長的因素之一。

此外，北美國家腫瘤和癌症病例數量的增加以及老年人口比例的增加也是推動腫瘤消融市場成長的主要因素之一。

主要進展

  • 2023 年 12 月－Popular Equipment Finance 收購了 Quantum Surgical 的 Epione® 機器人。 Epione(R) 機器人是一個機器人平台，專為無法手術的腹部腫瘤的早期治療而設計。 Epione(R) 在美國癌症中心使用，於 2023 年 5 月治療了第一位癌症患者。 Quantum Surgical 是一家法國醫療機器人公司，透過標準化治療提供一種新的癌症治療方法。 Epione® 在歐洲獲得了針對腹部和肺部腫瘤的 CE 標誌，並獲得了 FDA 針對腹部腫瘤的批准。可在維勒瑞夫古斯塔夫·魯西癌症中心和里昂臨終關懷醫院購買。 Epione® 已在全球治療了 300 多名患者，積極的用戶回饋加速了其在美國的採用。
  • 2023 年 3 月 - AngioDynamics 與 Minimax Medical 合作，進行產品系列的國際分銷。此次合作包括 MiniMax Medical 的腫瘤和結節射頻消融系統，並增強了 Angiodynamics 支持全球醫療保健部門改善患者生活的能力。 Minimax Medical 提供最具創新性的 RFA 設備，與 AngioDynamics 在腫瘤消融市場上的合作已超過 18 年。此次合作增強了 AngioDynamics 支援全球醫療保健產業改善患者生活的能力。 Minimax醫療控股集團是一家國際醫療科技集團，在多個領域提供微創醫療設備。
  • 2022 年 3 月 - Quantum Surgical 的 Epione® 機器人獲得 FDA 510(k) 許可，這是一種用於微創肝癌治療的機器人輔助技術。 Epione(R) 使臨床醫生能夠進行安全有效的經皮腫瘤消融術，這是一種透過將針頭插入皮膚來破壞腫瘤的微創治療方法。 FDA 的 510(k) 許可授權 Epione® 介入腫瘤機器人在美國進行商業性銷售和使用，以促進早期肝病治療。 Quantum Surgical 計劃將 Epione(R) 平台擴展到其他器官，並開發基於人工智慧的決策支援功能。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球腫瘤消融市場：依技術分類

  • 介紹
  • 射頻 (RF) 消融術
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 微波消融
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 冷凍療法
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他技術
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球腫瘤消融市場：依治療方法分類

  • 介紹
  • 手術消融
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 腹腔鏡消融術
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 經皮消融術
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球腫瘤消融市場：依應用分類

  • 介紹
  • 肝癌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 肺癌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 腎癌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 骨轉移
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他用途
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球腫瘤消融市場：按地區

  • 介紹
  • 北美洲
    • 依技術
    • 依治療方法
    • 按用途
    • 按國家/地區
  • 南美洲
    • 依技術
    • 依治療方法
    • 按用途
    • 按國家/地區
  • 歐洲
    • 依技術
    • 依治療方法
    • 按用途
    • 按國家/地區
  • 中東/非洲
    • 依技術
    • 依治療方法
    • 按用途
    • 按國家/地區
  • 亞太地區
    • 依技術
    • 依治療方法
    • 按用途
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Healthtronics, Inc.
  • Medtronic, PLC
  • Sonacare Medical
  • Boston Scientific Corporation
  • Edap TMS SA
  • Misonix, Inc.
  • Galil Medical, Inc.
  • Neuwave Medical, Inc.
  • Mermaid Medical A/S
  • Angiodynamics, Inc.
簡介目錄
Product Code: KSI061611901

The tumor ablation market was evaluated at US$1.291 billion in 2022 and is projected to grow at a CAGR of 12.10% to reach a market size of US$2.872 billion by 2029.

An image-guided technique generally employed for treating tumors and cancers in the lungs, kidneys, liver, bone, etc., is termed "tumor ablation". The high efficiency and cost-effectiveness offered by tumor ablation techniques are driving its demand in the global market. The technique is usually done by different means like cryoablation, radiofrequency ablation, microwave ablation, and others.

The imaging technique employed in tumor ablation provides efficient results in the diagnosis and prevention of tumors in their early stages. The rising cases of cancer and tumors are increasing the demand for tumor ablation techniques in the global market. The increasing awareness about cancer and the need to diagnose and treat cancer in its early stages is pushing the market value of these techniques globally.

The rise in the number of health and tumor-treating specialty hospitals is increasing the availability of tumor ablation techniques to people. Their efficiency in diagnosing and cost-efficiency are increasing the acceptability and applications of tumor ablation in the global market. The higher investment of major companies in the research and development sector of tumor ablation is also giving potential to the global tumor ablation market growth.

The support offered by governments and governmental agencies is also increasing the acceptability and availability of tumor ablation techniques. The growing geriatric population and the increasing rate of tumors are also some of the important factors driving the global tumor ablation market growth.

Market Drivers:

  • Rising cases of cancer are anticipated to propel the global tumor ablation market.

The rising cases of cancer and the increasing number of cancer patients are one of the major factors driving the global tumor ablation market growth. The lifestyle and modern diet of people have increased the rate of tumors and cancers in people. The rising cases of tumors have also resulted in the growing demand for treatment and diagnosis methods like tumor ablation in the global market.

The data from the American Cancer Society states that about 1,762,450 new cases of cancer or tumors are diagnosed in the United States each year. The rising cases of cancer and mortality rates due to cancer are increasing the demand for tumor ablation in the American market. The number of deaths due to cancer was reported as 606,880 in the United States by the American Cancer Society. Less efficient diagnosis and treatment techniques are resulting in cancer and tumor deaths around the world.

The WHO (World Health Organisation) claims that countries with less economic stability are showing more tumor and cancer cases compared to countries with high economic stability. The IUCC (International Union for Cancer Control) states that one in every 6 deaths around the globe is due to cancer or tumor. An approximate 70% mortality rate due to cancer is reported in countries with less economic stability and development. The need for better diagnosis techniques and treatment methods is boosting the global tumor ablation market. The rising need and demand for tumor ablation techniques are pushing the market demand and market value of the global tumor ablation market.

  • Technological advancements in ablation devices would bolster the market growth.

The technological advancements and up-gradation in research and development techniques employed in ablation devices are stimulating the global tumor ablation market growth. The high research and development investments made by several companies are raising the market share of the global tumor ablation market in the global healthcare and medical sector. The continuous up-gradation and developments in the healthcare and medical fields globally are also pushing the market for tumor ablation techniques to a certain level.

The introduction of cryoablation, microwave ablation, and other techniques has been certain discovery that has boosted the global market of tumor ablation. The application of the latest technologies in treating and diagnosing cancer has upgraded the techniques of tumor ablation to a new level. According to reports by IUCC (International Union for Cancer Control), about 167 billion USD is spent on the research and development process in cancer treatment.

North America is expected to dominate the market.

The North American region is expected to dominate the global tumor ablation market in the forecasted years. The increasing investments made by government organizations and several companies in this region in cancer treatment and diagnosis techniques are one of the factors boosting tumor ablation market growth.

The increasing cases of tumors and cancers and the increasing rate of the geriatric population in North American countries are also some of the major factors fuelling the market growth of the tumor ablation market.

Key Developments:

  • December 2023- Popular Equipment Finance acquired Quantum Surgical's Epione(R) robot, a robotic platform designed for early and curative treatment of inoperable abdomen tumors. The Epione(R) used by a US cancer center, where it treated the first cancer patient in May 2023. Quantum Surgical, a French medical robotics company, offers a new approach to cancer treatment by standardizing access to care. The Epione(R) is CE-marked in Europe for abdomen and lung tumors and FDA-cleared for abdominal tumors. It is available at Gustave Roussy Cancer Center in Villejuif and Hospices Civils de Lyon. Over 300 patients have been treated worldwide with Epione(R), and positive feedback from users helped accelerate its adoption in the US territory.
  • March 2023- AngioDynamics partnered with Minimax Medical for international distribution of its product portfolio. The partnership includes Minimax Medical's Radiofrequency Ablation System for tumors and nodules and enhances AngioDynamics' ability to support the healthcare sector in improving patients' lives globally. Minimax Medical, which offers some of the most transformative RFA devices, partnered with AngioDynamics for over 18 years in the tumor ablation market. The partnership strengthens AngioDynamics' ability to support the healthcare sector in improving patients' lives globally. Minimax Medical Holding Group is an international medical science and technology group that provides minimally invasive devices in various fields.
  • March 2022- Quantum Surgical received FDA 510(k) clearance for its Epione(R) robot, a robotic-assisted technology for minimally invasive liver cancer treatment. Epione(R) allows clinicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment where a needle is inserted through the skin to destroy the tumor. The FDA 510(k) clearance permits the commercial sale and use of the Epione(R) interventional oncology robot in the United States to facilitate early-stage liver disease treatment. Quantum Surgical plans to extend the Epione(R) platform to other organs and develop artificial intelligence-based decision-support features.

Segmentation:

By Technology

  • Radiofrequency (Rf) Ablation
  • Microwave Ablation
  • Cryoablation
  • Other Technologies

By Mode of Treatment

  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation

By Application

  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Bone Metastasis
  • Other Applications

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL TUMOR ABLATION MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Radiofrequency (Rf) Ablation
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Microwave Ablation
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Cryoablation
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Other Technologies
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL TUMOR ABLATION MARKET BY MODE OF TREATMENT

  • 6.1. Introduction
  • 6.2. Surgical Ablation
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Laparoscopic Ablation
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Percutaneous Ablation
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL TUMOR ABLATION MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Liver Cancer
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Lung Cancer
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Kidney Cancer
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Bone Metastasis
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Other Applications
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness

8. GLOBAL TUMOR ABLATION MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technology
    • 8.2.2. By Mode of Treatment
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technology
    • 8.3.2. By Mode of Treatment
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technology
    • 8.4.2. By Mode of Treatment
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technology
    • 8.5.2. By Mode of Treatment
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technology
    • 8.6.2. By Mode of Treatment
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Healthtronics, Inc.
  • 10.2. Medtronic, PLC
  • 10.3. Sonacare Medical
  • 10.4. Boston Scientific Corporation
  • 10.5. Edap TMS S.A.
  • 10.6. Misonix, Inc.
  • 10.7. Galil Medical, Inc.
  • 10.8. Neuwave Medical, Inc.
  • 10.9. Mermaid Medical A/S
  • 10.10. Angiodynamics, Inc.